EUVIMEDEUVIMED entdecken
Crossref

History of the discovery and development of Biomodulina T (InmunyVital®), a useful immunomodulator with a broad range of clinical applications

Roman R Rodriguez Martin, Olivia Gonzalez Gonzalez, Carolina Rodriguez Gonzalez, Rene R Rodriguez Gonzalez

International Immunopharmacology · 2023

DOI: 10.1016/j.intimp.2023.110167 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Roman R Rodriguez Martin und 3 weiteren Autor:innen. Beteiligte Einrichtung: BIOLONG Corporation, USA. Electronic address: info@inmunyvital.com. Hauptthemen laut MEDLINE: Autoimmune Diseases, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Biomodulina T (InmunyVital®) is a thymic factor that modulates immune response and inflammation. Biomodulina T stimulates the differentiation, maturation and proliferation of T cells. Additionally, Biomodulina T improves the ability of T cells to produce cytokines, therefore enhancing T lymphocyte function. Biomodulina T stimulates the thymus gland and, thus, promotes the recovery of normal thymus size in children with thymic hypoplasia and restores the functions of immunosenescent T cells in aging people. In 1984 Rodriguez Martin RR established the laboratory of Biomodulators, where he created and developed an immunomodulatory thymic factor that he named "Biomodulina T." The biological activity of Biomodulina T was demonstrated in several studies. An extensive series of preclinical toxicological studies were conducted and these studies demonstrated that Biomodulina T is an active and safe thymic factor. Clinical trials were conducted with Biomodulina T in patients with immunodeficiency and infections, autoimmune diseases, older adults with recurrent respiratory infections, and cancer. In 1994, we obtained the approval of Biomodulina T as an immunomodulatory drug. This article identifies the milestones involved in the development of Biomodulina T. Since its discovery more than 35 years ago, reports show that Biomodulina T is a modulator of immune response and inflammation that is very useful for restoring the immune system in young and elderly people with immunodeficiencies, autoimmune diseases, and infections. Biomodulina T is also useful as an immunotherapeutic agent for improving immune responses in cancer and vaccines, for reversing immunosenescence and for improving healthspan in aging.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Autoimmune DiseasesNeoplasmsMaleChildHumansAgedThymus GlandT-LymphocytesAgingImmunologic FactorsAdjuvants, ImmunologicInflammation

Stichwörter der Autor:innen

Biomodulina TCOVID-19ImmunomodulationImmunosenescenceImmunotherapyInmunyVitalMultiple sclerosisT cellsThymic factorThymus factor

Substanzen

Immunologic FactorsAdjuvants, Immunologic

Autor:innen und Institutionen

  • BIOLONG Corporation, USA. Electronic address: info@inmunyvital.com.
  • BIOLONG Corporation, USA.

Zitieren

APA

Rodriguez Martin, R. R., Gonzalez Gonzalez, O., Rodriguez Gonzalez, C., & Rodriguez Gonzalez, R. R. (2023). History of the discovery and development of Biomodulina T (InmunyVital®), a useful immunomodulator with a broad range of clinical applications. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.110167

Vancouver

Rodriguez Martin RR, Gonzalez Gonzalez O, Rodriguez Gonzalez C, Rodriguez Gonzalez RR. History of the discovery and development of Biomodulina T (InmunyVital®), a useful immunomodulator with a broad range of clinical applications. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.110167

BibTeX
@article{RodriguezMartin2023,
  author = {Rodriguez Martin, Roman R and Gonzalez Gonzalez, Olivia and Rodriguez Gonzalez, Carolina and Rodriguez Gonzalez, Rene R},
  title = {History of the discovery and development of Biomodulina T (InmunyVital®), a useful immunomodulator with a broad range of clinical applications},
  journal = {International Immunopharmacology},
  year = {2023},
  doi = {10.1016/j.intimp.2023.110167}
}
Kostenlos starten →